Abstract
OBJECTIVE: Peripheral infusions of glucagon-like peptide-1 (GLP-1) in humans have been shown to inhibit gastrointestinal motility and decrease hunger and energy intake. However, these investigations used supraphysiological doses. The objective of this study was to investigate the effects of a GLP-1 infusion in a physiological dose on appetite sensations, energy intake, gastric emptying, energy and substrate metabolism.
METHODS: Eighteen obese men participated in the placebo-controlled, randomized, single-blinded, cross-over study with infusion of GLP-1 or saline. Resting metabolic rate (RMR) and substrate oxidations were measured by ventilated hood before and after an energy-fixed breakfast. Gastric emptying was measured using paracetamol as a marker. Visual analogue scales were used to assess appetite sensations, thirst and comfort throughout the experiment and palatability of the test meals. Blood was sampled for analysis of hormones (GLP-1, GLP-2, glucose-dependent insulinotropic polypeptide (GIP), insulin, glucagon), and substrates (glucose, lactate, non-esterified fatty acids (NEFA), triacylglycerol (TAG)). Ad libitum energy intake at lunch was registered.
RESULTS: Following the breakfast, GLP-1 infusion suppressed ratings of hunger and prospective food consumption (P<0.05), whereas all other subjective ratings and ad libitum energy intake were unaffected. RMR, carbohydrate oxidation and gastric emptying rate were lower during the GLP-1 infusion compared with the saline infusion (P<0.001, P<0.05, P<0.0001, respectively). All plasma hormone and substrate profiles, except NEFA, were significantly reduced by GLP-1 (P<0.0001).
CONCLUSION: It is concluded that GLP-1 in physiological concentrations powerfully reduces the rate of entry of nutrients into the circulation by a reduction of gastric emptying rate in obese subjects. The effect of GLP-1 on appetite and food intake may be beneficial in weight reduction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Varndell IM, Bishop AE, Sikri KL, Uttenthal LO, Bloom SR, Polak JM . Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry J Histochem Cytochem 1985 33: 1080–1086.
Eissele R, Göke R, Willemer S, Harthus H-P, Vermeer H, Arnold R, Göke B . Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man Eur J Clin Invest 1992 22: 283–291.
Kreymann B, Williams G, Ghatei MA, Bloom SR . Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 1987 ii: 1300–1303.
Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V . Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns J Endocrinol 1993 138: 159–166.
Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W . Glucagon-like peptide-1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut Scand J Gastroenterol 1995 30: 892–896.
Ørskov C, Wettergren A, Holst JJ . Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day Scand J Gastroenterol 1996 31: 665–670.
Flint A, Raben A, Astrup A, Holst JJ . Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 1998 101: 515–520.
Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM . Glucagon-like peptide-1 (GLP-1) increases the period of postprandial satiety and slows gastric emptying in obese humans Am J Clin Nutr 1998 68: 525–530.
Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, Hellström PM . Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men Int J Obes Relat Metab Disord 1999 23: 304–311.
Gutswiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C . Glucagon-like peptide-1: a potent regulator of food intake in humans Gut 1999 44: 81–86.
Schjoldager B, Mortensen P-E, Christiansen J, Ørskov C, Holst J . GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man Dig Dis Sci 1989 35: 703–708.
O'Halloran DJ, Nikou GC, Kreymann B, Ghatei MA, Bloom SR . Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man J Endocrinol 1990 126: 169–173.
Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ . Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man Scand J Gastroenterol 1994 29: 501–505.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 1997 273: (Endocrinol Metab 36): E981–E988.
Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R, Strader CD . Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation Peptides 1998 19: 869–875.
Shalev A, Holst JJ, Keller U . Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man Eur J Clin Invest 1997 27: 10–16.
Flint A, Raben A, Holst JJ, Astrup A . The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans Int J Obes Relat Metab Disord 2000 24: 288–298.
Raben A, Mygind E, Saltin B, Astrup A . Lower activity of oxidative key enzymes and smaller fiber areas in skeletal muscle of post-obese women Am J Physiol Endocrinol Metab 1998 275: E487–494.
Flint A, Raben A, Blundell JE, Astrup A . Reproducibility, validity and power of visual analogue scales in assessment of subjective appetite sensations in single meal test studies Int J Obes Relat Metab Disord 2000 24: 38–48.
Klausen B, Toubro S, Astrup A . Age and sex effects on energy expenditure Am J Clin Nutr 1997 65: 895–907.
Costill DL . Carbohydrates for exercise: dietary demands for optimal performance Int J Sports Med 1988 9: 1–18.
Fellows IW, Macdonald IA . An automated method for the measurement of oxygen consumption and carbon dioxide excretion in man Clin Phys Physiol Meas 1985 6: 349–355.
Elia M, Livesey G . Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. In: Simopoulus AP (ed). Metabolic control of eating, energy expenditure and the bioenergetics of obesity. World Review of Nutrition and Diet 70: Karger: Basel 1992 68–131.
Wahlefeld AW . Triglycerides. Determination after enzymatic hydrolysis. In: Bergmayer HU (ed). Methods of enzymatic analysis, 2nd ed. Academic Press: New York 1974.
Deeg R, W Kraemer, J Ziegenhorn: Kinetic determination of serum glucose by use of the hexokinase/glucose-6-phosphate dehydrogenase method . J Clin Chem Clin Biochem 1980 18: 49–52.
Noll F . L-(+)-Lactate. Determination with LDH, GPT and NAD. In: Bergmayer HU (ed).Methods of enzymatic analysis, 2nd ed. Academic Press: New York 1974.
Albano JDM, Ekins RP, Maritz G, Turner RC . A sensitive precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties Acta Endocrinol 1972 70: 487–509.
Ørskov C, Rabenhøj A, Wettergren A, Kofod H, Holst JJ . Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans Diabetes 1994 43: 535–539.
Ørskov C, Jeppesen J, Madsbad S, Holst JJ . Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine J Clin Invest 1991 87: 415–423.
Hartmann B, Johnsen AH, Ørskov C, Holst JJ . Structure, analysis and secretion of human glucagon-like peptide-2 (GLP-2). (Abstract). Diabetes 1996 45 (Suppl 2): 300A.
Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L . Diminished immunoreactive gastric inhibitory polypeptide response to a meal newly diagnosed type 1 (insulin-dependent) diabetics J Clin Endocrinol Metab 1983 56: 1306–1312.
Kirsten WJ, Hesselius GU . Rapid, automatic, high capacity Dumas determination of nitrogen Microchem J 1983 28: 529–547.
Diggle PJ, Liang K-Y, Zegler SL . Analysis of longitudinal data Clarendon Press: Oxford 1994.
Senn S . Cross-over trials in clinical research Wiley: New York 1993.
Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, Morgan LM . No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man Br J Nutr 1999 81: 273–279.
Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DA, Møller M, Sheikh SP . Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats Am J Physiol 1996 271: (Regulatory Integrative Comp Physiol 40): R848–R856.
Holst JJ . Enteroglucagon A Rev Physiol 1997 59: 257–271.
Larsen PJ, Tang-Christensen M, Holst JJ, Ørskov C . Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem Neuroscience 1997 77: 257–270.
Schick RR, vorm Walde T, Zimmermann JP, Schusdziarra V, Classen M . Glucagon-like peptide 1-a novel brain peptide involved in feeding regulation. In: Ditschuneit H, Gries FA, Hauner H, Schusdziarra V, Wechsler JG (eds). Obesity in Europe. Libbey & Company; 1993 363–367.
Turton MD, O'Shea D, Gunn I, Beak SA, Edwards MB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR . A role for glucagon-like peptide-1 in the central regulation of feeding Nature 1996 379: 69–72.
Ørskov C, Poulsen SS, Møller M, Holst JJ . Glucagon-like peptide 1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide 1 Diabetes 1996 45: 832–835.
Goldstone AP, Mercer JG, Gunn I, Moar KM, Edwards CM, Rossi M, Howard JK, Rasheed S, Turton MD, Small C, Heath MM, O'Shea D, Steere J, Meeran K, Ghatei MA, Hoggard N, Bloom SR . Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents FEBS Lett 1997 415: 134–138.
Van Dijk G, Thiele TE, Donahey CK, Campfield IA, Smith FJ, Burn P, Bernstein IL, Woods SC, Seeley RJ . Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain Am J Physiol 1996 271: R1096–R1100.
Drewes C, Nauck MA, Horn R, Holst J, Schmiegel W, Brabant G . A liquid mixed meal or exogenous glucagon-like peptide-1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers Acta Diabetol 1997 34: 230–234.
Shalev A, Vosmeer S, Keller U . Absence of short-term effects of glucagon-like peptide-1 and of hyperglycemia on plasma leptin levels in man Metabolism 1997 46: 723–725.
Todd JF, Wilding JPH, Edwards CMB, Khan FA, Ghatei MA, Bloom SR . Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus Eur J Clin Invest 1997 27: 533–536.
Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML . Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms Am J Physiol 1997 273: G920–927.
Sepple CP, Read NW . Gastrointestinal correlates of the development of hunger in man Appetite 1989 13: 183–191.
Read N, French S, Cunningham K . The role of the gut in regulating food intake in man Nutr Rev 1994 52: 1–10.
Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ . Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene Nature Med 1996 2: 1254–1258.
Acknowledgements
The authors gratefully thank John Lind, Inge Timmermann, Bente Knap, Jannie Møller, Charlotte Kostecki, Karina G Larsen, Lone K Larsen, Trine Jessen, Lene Albaek, Bolette Hartmann and Helle Angelo for expert technical assistance. This study was supported by the Danish Research and Development Program for Food Technology 1995-1997 (FØTEK II, 9315013) and the Danish Medical Research Council (12-1610-1). JJ Holst was supported by the Danish Biotechnology Program.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flint, A., Raben, A., Ersbøll, A. et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 25, 781–792 (2001). https://doi.org/10.1038/sj.ijo.0801627
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801627
Keywords
This article is cited by
-
Competing paradigms of obesity pathogenesis: energy balance versus carbohydrate-insulin models
European Journal of Clinical Nutrition (2022)
-
Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice
Brain Structure and Function (2022)
-
The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial
Diabetologia (2020)
-
A novel peptide RIFV suppresses human adipocyte differentiation through the inhibition of C/EBP-β expression
Nutrition & Metabolism (2019)
-
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Diabetologia (2019)